For research use only. Not for therapeutic Use.
YE6144 is a prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 selectively suppresses IRF5 activity through inhibition of IRF5 phosphorylation[1].
YE6144 (1 or 3 μM; 30 min) inhibits the phosphorylation of IRF5 in both human PBMCs and mouse splenocytes[1].
YE6144 (0-10 μM; 30 min) inhibits the production of type I IFNs with an IC50 of approximately 0.09 μM in human HC PBMCs[1].
YE6144 (40.0 mg/kg; s.c.; once) suppresses the progression of mouse systemic lupus erythematosus[1].
Catalog Number | I042834 |
Synonyms | (2S)-1-N-[6-fluoro-3-[(E)-2-(6-morpholin-4-ylpyridazin-3-yl)ethenyl]-1H-indazol-5-yl]butane-1,2-diamine;hydrochloride |
Molecular Formula | C21H27ClFN7O |
Purity | ≥95% |
InChI | InChI=1S/C21H26FN7O.ClH/c1-2-14(23)13-24-20-11-16-18(26-27-19(16)12-17(20)22)5-3-15-4-6-21(28-25-15)29-7-9-30-10-8-29;/h3-6,11-12,14,24H,2,7-10,13,23H2,1H3,(H,26,27);1H/b5-3+;/t14-;/m0./s1 |
InChIKey | NUNTVCPRDFANCY-ZOWAZICSSA-N |
SMILES | CCC(CNC1=C(C=C2C(=C1)C(=NN2)C=CC3=NN=C(C=C3)N4CCOCC4)F)N.Cl |
Reference | [1]. Ban T, et al. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nat Commun. 2021 Jul 19;12(1):4379. |